Award Winning Technology

MeMed has won multiple highly competitive contracts and awards from the US Department of Defense and the European Commission, totaling over $25 million.

Project name: A novel host-protein Point-Of-Care platform for differentiating bacterial vs viral infections: Transition from prototype to product

 

Funding: $4,079,159

 

Aim:  To support transfer to manufacturing of MeMed's pioneering point of care platform (MeMed Key™) that distinguishes bacterial from viral infections

The two-year grant from the DOD's Congressionally Directed Medical Research Programs (CDMRP) is contributing to the following activities: (i) Finalize design and facilitate manufacturing of MeMed Key™; (ii) Facilitate manufacturing of MeMed Key™ cartridge and reagents; (iii) Develop connectivity capabilities.

Project name: DTRA ‘FEVER’ program – Fieldable tests for Early Viral Exposure Response

 

Funding: $10,231,791

 

Aim: To advance the ongoing transition of central laboratory MeMed BV™ in an ELISA format onto MeMed Key™ point-of-care platform for accurate and early detection of the infection cause.

 

Partners: MRI Global

The two and a half year contract from the US Department of Defense (DTRA) will help fund prototyping MeMed key™ for distinguishing bacterial from viral infections. Notably, in addition to allowing measurements of bacterial versus viral proteins, MeMed key™ opens the way to a variety of rapid multiplex-protein measurements at the point-of-care with lab quality precision, which has broad applications. The project will also evaluate and potentially expand the test menu to detect early infections, even at the pre-symptomatic stage. 
 

The following international projects were co-funded as part of the FP7 (Seventh Framework) and Horizon 2020 EU research and innovation programs

Project name: AutoPilot-Dx

 

Funding: €2,300,000

 

Aim: Deployment of MeMed BV™ ELISA format (ImmunoXpert™) in top EU hospitals.

 

Partners: University of Perugia, University Hospital Mannheim, Tecan, Quantify Research, and MeMed

AutoPilot-Dx is an international consortium funded by the EU and led by MeMed with members from leading medical centers and industry that are coordinating the deployment of MeMed BV™ ELISA format in Europe to reduce antibiotic misuse in hospitals. Funds are being used to further solidify clinical utility and cost-effectiveness of MeMed BV™ ELISA format, with the goal of monitoring the management of 1,200 children with respiratory tract infections or fever without source. The two-year award was granted through the prestigious Horizon 2020 Fast Track to Innovation Pilot, which recognizes outstanding business innovators. 

Project name: Respiratory-ImmunoDx

 

Funding: €3,000,000

 

Aim: Clinical validation of host biomarker signature for distinguishing bacterial versus viral lower respiratory tract infections  in adults at the point-of-need

 

Partners: Rambam Health Care Campus, The Royal Free London NHS Foundation Trust and Hannover Medical School

The three-year award was granted through Horizon 2020’s Small and Medium-sized Enterprise (SME) instrument, which targets high potential SMEs with groundbreaking products that have the potential to profoundly impact the EU economy and global healthcare. MeMed's proposal received top place out of 90 competitive applicants. Funds are being used to accelerate development of MeMed Key and validate MeMed BV on adults patients.

Project name: Tailored-Treatment

 

Funding: €6,000,000

 

Aim: To validate pioneering diagnostic technologies to improve management of hospitalized patients with acute infection, and guide antibiotic treatment

 

Partners: Erasmus MC, Rotterdam, University Medical Center, Utrecht, Hadassah University Hospital, IBEXPERTS, University of Gothenburg, Noray Bioinformatics, and MeMed

At the heart of the Tailored-Treatment project is a prospective international clinical study designed to recruit and monitor 1200 hospitalized patients with respiratory tract and/or bloodstream infections. Cutting edge high-throughput techniques are used to measure the transcriptomic, proteomic and genomic fingerprint of these patients as well as their microbiome. The expected result is a unique multifaceted dataset that will be used to identify novel host-pathogen interactions and discover new biological markers of infection.